thymine has been researched along with Cancer of Head in 8 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "We tested 17 malignant mucosal melanomas of the head and neck for the thymine (T)-->adenine (A) missense mutation at nucleotide 1796 in the BRAF gene using direct sequencing and a newly developed assay that uses a novel primer extension method (Mutector assay)." | 3.72 | Exon 15 BRAF mutations are uncommon in melanomas arising in nonsun-exposed sites. ( Begum, S; Cohen, Y; Esche, C; Goldenberg, D; Lavie, O; Rosenbaum, E; Sidransky, D; Westra, WH, 2004) |
| "203 head and neck cancer patients and 201 healthy controls were genotyped for functional polymorphisms of CYP2A13 and UGT1A7 genes using polymerase chain reaction-restriction fragment length polymorphism, denaturing high-performance liquid chromatography and sequencing." | 1.36 | Polymorphisms in CYP2A13 and UGT1A7 genes and head and neck cancer susceptibility in North Indians. ( Ahuja, M; Khullar, M; Panda, N; Sharma, R, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Soares, AC | 1 |
| Soares, JC | 1 |
| Rodrigues, VC | 1 |
| Follmann, HDM | 1 |
| Arantes, LMRB | 1 |
| Carvalho, AC | 1 |
| Melendez, ME | 1 |
| Fregnani, JHTG | 1 |
| Reis, RM | 1 |
| Carvalho, AL | 1 |
| Oliveira, ON | 1 |
| Niu, Y | 1 |
| Yuan, H | 1 |
| Shen, M | 1 |
| Li, H | 1 |
| Hu, Y | 1 |
| Chen, N | 1 |
| Sharma, R | 2 |
| Ahuja, M | 1 |
| Panda, N | 1 |
| Khullar, M | 2 |
| Panda, NK | 1 |
| Cohen, Y | 2 |
| Xing, M | 1 |
| Mambo, E | 1 |
| Guo, Z | 1 |
| Wu, G | 1 |
| Trink, B | 1 |
| Beller, U | 1 |
| Westra, WH | 2 |
| Ladenson, PW | 1 |
| Sidransky, D | 2 |
| Emura, T | 1 |
| Nakagawa, F | 1 |
| Fujioka, A | 1 |
| Ohshimo, H | 1 |
| Kitazato, K | 1 |
| Rosenbaum, E | 1 |
| Begum, S | 1 |
| Goldenberg, D | 1 |
| Esche, C | 1 |
| Lavie, O | 1 |
| Wolberg, WH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Trial of BAY 43-9006 (Sorafenib) and Bevacizumab in Refractory Solid Tumors With Biologic and Proteomic Analysis[NCT00095459] | Phase 1 | 57 participants (Actual) | Interventional | 2004-11-02 | Completed | ||
| A Phase II Study of Sorafenib and Bevacizumab in Epithelial Ovarian, Fallopian, and Peritoneal Cancer[NCT00436215] | Phase 2 | 55 participants (Actual) | Interventional | 2006-12-12 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module. (NCT00436215)
Timeframe: up to 28 months
| Intervention | Participants (Count of Participants) |
|---|---|
| BAY 43-9006 + Bevacizumab | 54 |
Progression free survival is defined by the number of weeks between the first day of treatment and the date of cancer progression. (NCT00436215)
Timeframe: up to 28 months
| Intervention | Weeks (Mean) |
|---|---|
| BAY 43-9006 + Bevacizumab | 26 |
Clinical response rate is defined as the percentage of participants with a complete response (CR) or partial response (PR) per the Response Evaluation Criteria in Solid Tumors (RECIST). CR is disappearance of all target lesions. PR is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. Progressive disease (PD) is a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. Stable disease (SD) is neither sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started lasting at least 6 months. (NCT00436215)
Timeframe: patients were followed for a median of 18 weeks (range 1-116 weeks)
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Complete Response | Partial Response | Progressive Disease | Stable Disease | |
| BAY 43-9006 + Bevacizumab | 0 | 19 | 21 | 60 |
8 other studies available for thymine and Cancer of Head
| Article | Year |
|---|---|
Microfluidic-Based Genosensor To Detect Human Papillomavirus (HPV16) for Head and Neck Cancer.
Topics: Adenine; Carcinoma, Squamous Cell; Cell Line, Tumor; Chitosan; Chondroitin Sulfates; DNA, Single-Str | 2018 |
Association between cyclooxygenase-2 gene polymorphisms and head and neck squamous cell carcinoma risk.
Topics: 3' Untranslated Regions; Adenine; Adult; Aged; Alcohol Drinking; Carcinoma, Squamous Cell; Case-Cont | 2014 |
Polymorphisms in CYP2A13 and UGT1A7 genes and head and neck cancer susceptibility in North Indians.
Topics: Alcohol Drinking; Aryl Hydrocarbon Hydroxylases; Carcinogens; Chromatography, High Pressure Liquid; | 2010 |
Hypermethylation of carcinogen metabolism genes, CYP1A1, CYP2A13 and GSTM1 genes in head and neck cancer.
Topics: Adenine; Alcohol Drinking; Aryl Hydrocarbon Hydroxylases; Carcinogens; Carcinoma, Squamous Cell; CpG | 2010 |
BRAF mutation in papillary thyroid carcinoma.
Topics: Adenine; Carcinoma, Papillary; Case-Control Studies; Head and Neck Neoplasms; Humans; Lung Neoplasms | 2003 |
BRAF mutation in papillary thyroid carcinoma.
Topics: Adenine; Carcinoma, Papillary; Case-Control Studies; Head and Neck Neoplasms; Humans; Lung Neoplasms | 2003 |
BRAF mutation in papillary thyroid carcinoma.
Topics: Adenine; Carcinoma, Papillary; Case-Control Studies; Head and Neck Neoplasms; Humans; Lung Neoplasms | 2003 |
BRAF mutation in papillary thyroid carcinoma.
Topics: Adenine; Carcinoma, Papillary; Case-Control Studies; Head and Neck Neoplasms; Humans; Lung Neoplasms | 2003 |
Thymidine kinase and thymidine phosphorylase level as the main predictive parameter for sensitivity to TAS-102 in a mouse model.
Topics: Animals; Antineoplastic Agents; Cell Division; Drug Combinations; Head and Neck Neoplasms; Humans; M | 2004 |
Exon 15 BRAF mutations are uncommon in melanomas arising in nonsun-exposed sites.
Topics: Adenine; DNA; Exons; Head and Neck Neoplasms; Humans; Melanocytes; Melanoma; Models, Genetic; Mutage | 2004 |
Biochemical approaches to prediction of response in solid tumors.
Topics: Adenocarcinoma; Antineoplastic Agents; Carbon Isotopes; Carcinoma, Hepatocellular; Carcinoma, Squamo | 1971 |